Page 18 - Read Online

Page 8 of 8 Qin et al. Vessel Plus 2020;4:2 I http://dx.doi.org/10.20517/2574-1209.2019.22

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Considering the retrospective nature of this study and the widely accepted use of rhPro-UK in China,
specific consent form was waived.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2020.

REFERENCES
1. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, et al. 2014 ESC/EACTS guidelines on myocardial revascularization. Rev Esp
Cardiol (Engl Ed) 2015;68:144.
2. Park SD, Baek YS, Lee MJ, Kwon SW, Shin SH, et al. Comprehensive assessment of microcirculation after primary percutaneous
intervention in ST-segment elevation myocardial infarction: insight from thermodilution-derived index of microcirculatory resistance
and coronary flow reserve. Coron Artery Dis 2016;27:34-9.
3. Kaul S. The “no reflow” phenomenon following acute myocardial infarction: mechanisms and treatment options. J Cardiol 2014;64:77-85.
4. Kodama T, Kondo T, Oida A, Fujimoto S, Narula J. Computed tomographic angiography-verified plaque characteristics and slowflow
phenomenon during percutaneous coronary intervention. JACC Cardiovasc Interv 2012;5:636-43.
5. Schwartz BG, Kloner RA. Coronary no reflow. J Mol Cell Cardiol 2012;52:873-82.
6. Sezer M, Cimen A, Aslanger E, Elitok A, Umman B, et al. Effect of intracoronary streptokinase administered immediately after primary
percutaneous coronary intervention on long-term left ventricular infarct size, volumes, and function. J Am Coll Cardiol 2019;54:1065-71.
7. Zhao L, Zhao Z, Chen X, Li J, Liu J, et al; Group of Prourokinase Phase IV Clinical Trials Investigators. Safety and efficacy of
prourokinase injection in patients with ST-elevation myocardial infarction: phase IV clinical trials of the prourokinase phase study.
Heart Vessels 2018;33:507-12.
8. Zhao QS, Li W, Li D, Liu T, Wang JH, et al. Clinical treatment efficiency of mechanical thrombectomy combined with rhPro-UK
thrombolysis for acute moderate/severe cerebral infarction. Eur Rev Med Pharmacol Sci 2018;22:5740-6.
9. Hao CH, Ding WX, Sun Q, Li XX, Wang WT, et al. Effect of human recombinant prourokinase (rhpro-UK) on thromboembolic stroke
in rats. Eur J Pharmacol 2018;818:429-34.
10. Hao C, Ding W, Xu X, Sun Q, Li X, et al. Effect of recombinant human prourokinase on thrombolysis in a rabbit model of
thromboembolic stroke. Biomed Rep 2018;8:77-84.
11. Geng W, Zhang Q, Liu J, Tian X, Zhen L, et al. A randomized study of prourokinase during primary percutaneous coronary intervention
in acute ST-segment elevation myocardial infarction. J Interv Cardiol 2018;31:136-43.
12. Han YL, Liu JN, Jing QM, Ma YY, Jiang TM, et al. The efficacy and safety of pharmacoinvasive therapy with prourokinase for acute
ST-segment elevation myocardial infarction patients with expected long percutaneous coronary intervention-related delay. Cardiovasc
Ther 2018;31:285-90.
13. Ettenson DS, Edelman ER. Local drug delivery: an emerging approach in the treatment of restenosis. Vasc Med 2000;5:97-102.
14. Reinstadler SJ, Baum A, Rommel KP, Eitel C, Desch S, et al. ST-segment depression resolution predicts infarct size and reperfusion
injury in ST-elevation myocardial infarction. Heart 2015;101:1819-25.
15. Taguchi E, Konami Y, Inoue M, Suzuyama H, Kodama K, et al. Impact of Killip classifcation on acute myocardial infarction: data from
the SAIKUMA registry. Heart Vessels 2017;32:1439-47.
16. Dijkmans PA, Senior R, Becher H, Porter TR, Wei K, et al. Myocardial contrast echocardiography evolving as a clinically feasible
technique for accurate, rapid, and safe assessment of myocardial perfusion: the evidence so far. J Am Coll Cardiol 2016;48:2168-77.